In this article, we will discuss 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts.
Penny stocks remain one of the most controversial corners of the market — capable of producing enormous gains, devastating losses, and endless debate among billionaire investors and hedge fund managers. While some legendary investors see penny stocks as dangerous speculation filled with manipulation and hype, others acknowledge that overlooked small-cap companies can occasionally become extraordinary multibaggers.
Investors inspired by Peter Lynch continue searching for overlooked small-cap companies before Wall Street discovers them. Lynch famously argued that individual investors can sometimes identify opportunities that institutional investors miss, particularly in smaller or lesser-known businesses. His Magellan Fund reportedly generated an annualized return of roughly 29.2% over 13 years, making him one of the greatest growth investors in history.
At the same time, hedge fund managers such as David Einhorn and Michael Burry have also repeatedly warned investors about speculative excess in highly volatile market segments. Einhorn recently warned that speculative retail behavior resembles prior bubble periods and argued that many overvalued stocks could eventually collapse when fundamentals fail to justify expectations.
Recent academic studies show why penny stocks continue attracting investors despite the risks. Research published on arXiv analyzing 167 penny stocks listed on India’s National Stock Exchange found that lower market-cap penny stocks significantly outperformed larger penny stocks, while lower P/E and lower price-to-book penny stocks also generated higher returns. Another major study published in the Journal of Banking & Finance found that roughly 30% of highly shorted stocks also had high hedge-fund ownership, demonstrating the enormous disagreement and speculative behavior often surrounding risky equities.
The appeal of penny stocks lies in their explosive upside potential. Investors are drawn to the possibility of discovering small companies before they achieve mainstream success, especially in emerging industries like biotechnology, AI, mining, clean energy, and fintech. However, penny stocks also carry some of the market’s highest risks, including poor liquidity, weak financials, and volatility.
With this context in mind, here are some of the best-rated penny stocks to buy according to Wall Street analysts.
Our Methodology
We used stock screeners to identify a list of penny stocks with upside potential of over 30%. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds. To make the list easier to navigate, we ranked the stocks in ascending order of their upside potential.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
7 Best Rated Penny Stocks to Buy According to Wall Street Analysts
7. Embecta Corp. (NASDAQ:EMBC)
Upside Potential: 32.01%
On May 18, Bank of America analyst Travis Steed lowered the firm’s price target on Embecta Corp. (NASDAQ:EMBC) to $3 from $11 while maintaining an Underperform rating on the shares. Following meetings with 34 medtech companies in Las Vegas, the analyst updated multiple healthcare valuation models to reflect what the firm described as a “new reality” for medtech stocks. Bank of America cited concerns surrounding a lack of major product cycles, the Affordable Care Act, and utilization-related uncertainties, inflationary pressures following geopolitical instability, and investor preference shifting toward artificial intelligence and data center investments rather than healthcare equities. The revised target reflects broader sector-wide caution despite Embecta’s established presence in diabetes care solutions.
Earlier, on May 6, Mizuho Financial Group lowered its price target on Embecta Corp. (NASDAQ:EMBC) to $5 from $12 while maintaining a Neutral rating. The adjustment came amid continued pressure across the broader medical technology sector, where analysts remain cautious regarding reimbursement trends, healthcare utilization patterns, and the pace of innovation-driven growth. Despite the lowered valuation targets, Embecta continues to maintain a significant position within the global diabetes care market through its specialized insulin delivery product portfolio.
Founded in 2022 and headquartered in Parsippany, Embecta Corp. (NASDAQ:EMBC) is a global medical technology company focused exclusively on diabetes care solutions. The company specializes in insulin delivery systems, including syringes and pen needles, while also investing in digital health technologies aimed at improving diabetes management and patient outcomes.
6. eHealth, Inc. (NASDAQ:EHTH)
Upside Potential: 39.66%
On May 8, Deutsche Bank analyst George Hill raised the firm’s price target on eHealth, Inc. (NASDAQ:EHTH) to $3 from $2 while maintaining a Hold rating on the shares. The revised target reflects improving operational execution and stronger financial momentum following the company’s recent quarterly performance. Analysts continue to monitor the company’s ability to expand enrollment volumes, improve customer acquisition efficiency, and strengthen profitability within the competitive online health insurance marketplace industry.
On May 6, eHealth, Inc. (NASDAQ:EHTH) reported first-quarter revenue of $88 million, exceeding consensus estimates of $81.27 million. Chief Executive Officer Derrick Duke stated that the stronger-than-expected results were driven by higher enrollment volume and favorable acquisition costs during the quarter. Management also highlighted meaningful progress toward fiscal 2026 strategic initiatives, including targeted cost reductions and readiness work supporting newly launched programs. Among the company’s major initiatives were the rollout of its lifetime advisory model and the introduction of a new final expense insurance product, both aimed at strengthening eHealth’s ability to help consumers navigate increasingly complex healthcare and insurance decisions.
Founded in 1997 and headquartered in Santa Clara, eHealth, Inc. (NASDAQ:EHTH) operates a leading private online marketplace for health insurance products. The company enables individuals, families, and small businesses to digitally compare, research, and enroll in health insurance plans across a broad range of providers and coverage categories.
While we acknowledge the potential of EHTH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than EHTH and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Best Rated Penny Stocks to Buy According to Wall Street Analysts.
Disclosure: None. Follow Insider Monkey on Google News.
